Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy

Fundamental and Clinical Pharmacology

Volumn 16, Issue 5, 2002, Pages 347-352

  Sasomsin, Patrinee ^a   Mentré, France ^a   Diquet, Bertrand ^a   Simon, François ^b   Brun Vezinet, Françoise ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Clinical response; Exposure; Pharmacodynamics; Pharmacokinetics; Zidovudine

Indexed keywords

ANTIGEN P24; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAG PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG TARGETING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOTHERAPY; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; VIROLOGY; AGED; AIDS RELATED COMPLEX; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ADULT; AGED; AIDS-RELATED COMPLEX; ANTI-HIV AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV CORE PROTEIN P24; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TIME FACTORS; ZIDOVUDINE;

EID: 0036434341     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2002.00126.x     Document Type: Article

References (19)

1. Acosta E.P., Page L.M., Fletcher C.V. Clinical pharmacokinetics of zidovudine: an update. Clin. Pharmacokinet. (1996) 30 251-262.
2. Langtry H.D., Campoli-Richards D.M. Zidovudine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs (1989) 37 408-450.
3. Stretcher B.N. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Clin. Pharmacokinet. (1995) 29 46-65.
4. Hoetelmans R.M.W., Burger D.M., Meenhorst P.L., Beijnen J.H. Pharmacokinetic individualization of zidovudine therapy. Clin. Pharmacokinet. (1996) 30 314-327.
5. Mentré F., Escolano S., Diquet B., Golmard J.L., Mallet A. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. Eur. J. Clin. Pharmacol. (1993) 45 397-407.
6. Noormohamed S.E., Henry W.K., Rhame F.S., Balfour H.H. Jr, Fletcher C.V. Strategies for control of zidovudine concentrations in serum. Antimicrob. Agents Chemother. (1995) 39 2792-2797.
7. Acosta E.P., Henry K., Page L.M., Erice A., Balfour H.H., Fletcher C.V. Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. Pharmacotherapy (1997) 17 424-430.
8. Fletcher C.V., Acosta E.P., Henry K. et al. Concentration-controlled zidovudine therapy. Clin. Pharmacol. Ther. (1998) 64 331-338.
9. Khoo S.H., Gibbons S., Back D.J. Therapeutic drug monitoring of HIV treatment. HIV & AIDS Current Trends (1999) 5 4-6.
10. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 271 1582-1586.
11. Wu H., Ding A.A. Population HIV-1 dynamics in vivo: An applicable models and inferential tools for virologic data from AIDS clinical trials. Biometrics (1999) 55 410-418.
12. th International Conference on AIDS, Montreal, June 1989, abstract MBP 343.
13. Lacroix C., Phan Hang T., Wojciechowski F., Duwoos H., Nouveau J., Diquet B. Simultaneous quantification of zidovudine and its metabolite in serum and urine by HPLC using column switching technique. J. Chromtogr. (1990) 525 240-245.
14. Huet S., Bouvier A., Gruet M.A., Jolivet E. Statistical Tool for Nonlinear Regression: A Practical Guide with S-PLUS Examples. Springer-Verlag, Berlin, 1996.
15. Fleiss J.L. The Design and Analysis of Clinical Experiments. John Wiley & Sons, New York, 1986, pp. 103-107.
16. Gieschke R., Fotteler B., Buss N., Steimer J.L. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-Positive patients. Clin. Pharmacokinet. (1999) 37 75-86.
17. Drusano G.L. Pharmacodynamics of antiretroviral chemotherapy. Infect. Control. Hosp. Epidemiol. (1993) 14 530-536.
18. Drusano G.L., Yuen G.J., Lambert J.S., Dolin R., Valentine F.T. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. Ann. Intern. Med. (1992) 116 562-566.
19. Amantea M.A., Forrest A., Northfelt D.W., Mamelok R. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related kaposi's sarcoma. Clin. Pharmacol. Ther. (1997) 63 301-311.